The $13 Million Company Teaching the Immune System to Hunt Cancer
Issued on behalf of GT Biopharma, Inc. (NASDAQ: GTBP) Three drugs in human trials. A platform licensed from one of the world's top cancer-research universities. A market cap smaller than a Manhattan apartment. For investors willing to look where almost no one is looking, GT Biopharma is...
Issued on behalf of GT Biopharma, Inc. (NASDAQ: GTBP) Three drugs in human trials. A platform licensed from one of the world's top cancer-research universities. A market cap smaller than a Manhattan apartment. For investors willing to look where almost no one is looking, GT Biopharma is...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.